$2.54
arrow_drop_down7.94%Key Stats | |
---|---|
Open | $2.77 |
Prev. Close | $2.77 |
EPS | -1.59 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $585.51M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 2.54 | 2.85 |
52 Week Range | 2.01 | 5.78 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -1.59 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Analyst Ratings For Allogene Therapeutics